Niemann-Pick disease (NPD) comprises a group of autosomal recessive lysosomal storage disorders characterized by the accumulation of sphingomyelin and cholesterol within the mononuclear phagocyte system [1]. The disease results from mutations in SMPD1 (Niemann-Pick type A and B) or NPC1/NPC2 (type C), leading to deficient activity of acid sphingomyelinase (ASM) or impaired cholesterol trafficking, respectively [2]. Clinical manifestations include hepatosplenomegaly, neurological deterioration, and in severe cases, premature death [3].
Treatment strategies for Niemann-Pick disease have evolved significantly, encompassing supportive care, enzyme replacement therapy, substrate reduction therapy, and emerging gene therapy approaches [4]. This comprehensive review examines current treatment modalities, clinical outcomes, and future therapeutic directions for these rare but devastating disorders.
Type A (NPD-A) results from severe acid sphingomyelinase deficiency due to SMPD1 mutations [5]. Classic infantile form presents in early infancy with:
Most patients do not survive beyond 2-3 years of age [10].
The neuropathological features of NPD-A include [11]:
Type B (NPD-B) presents with milder ASM deficiency [16]:
NPD-B is characterized by [21]:
Type C (NPC) involves defective intracellular cholesterol trafficking due to NPC1 (95%) or NPC2 (5%) mutations [26]:
The pathophysiology of NPC involves [33]:
Niemann-Pick disease is rare, with varying prevalence by type [38]:
SMPD1 Gene [42]:
NPC1 Gene [46]:
NPC2 Gene [50]:
ASM catalyzes the hydrolysis of sphingomyelin to ceramide and phosphocholine [53]. Deficiency leads to [54]:
NPC proteins are essential for cholesterol egress from lysosomes [59]:
| Age of Onset | Features |
|---|---|
| 2-6 months | Failure to thrive, hepatosplenomegaly |
| 6-12 months | Developmental delay, hypotonia |
| 12-18 months | Progressive neurodegeneration |
| 18-24 months | Spasticity, seizures, death |
| Age of Onset | Features |
|---|---|
| Childhood | Recurrent infections, hepatosplenomegaly |
| Adolescence | Delayed puberty, short stature |
| Adulthood | Pulmonary disease, bone disease |
| Age of Onset | Features |
|---|---|
| Perinatal | Neonatal cholestasis, hepatosplenomegaly |
| Childhood | Vertical gaze palsy, ataxia |
| Adolescence | Psychiatric symptoms, seizures |
| Adulthood | Dementia, dystonia |
Olipudase alfa (Xenpozyme) is a recombinant human acid sphingomyelinase (rhASM) approved for treating non-central nervous system manifestations of NPD type B [67]:
Clinical trials demonstrate [74]:
Miglustat (Zavesca) is approved for NPC disease in Europe and is used off-label in the United States [75]:
Adverse effects [82]:
Neurological management [83]:
Systemic management [84]:
Monitoring recommendations [85]:
Gene therapy approaches [86]:
Other investigational therapies [87]:
Pulmonary Disease [88]:
Hepatosplenomegaly [92]:
Neurological Symptoms [96]:
Multiple trials are ongoing for NPD [^120]:
Vanier MT. Niemann-Pick disease type C. 2010. ↩︎
Schuchman EH, Desnick RJ. Niemann-Pick disease types A and B. 2017. ↩︎
Patterson MC, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C. 2019. ↩︎
Walkley SU, et al. Therapeutic approaches for Niemann-Pick disease. 2023. ↩︎
Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. 2007. ↩︎
Spitz DJ. Infantile neurovisceral forms of Niemann-Pick disease. 2013. ↩︎
Arsenault L, et al. Cherry-red spot in inherited metabolic disorders. 2022. ↩︎
Kelly DA, et al. Hepatosplenomegaly in lysosomal storage disorders. 2018. ↩︎
Wasserstein MP, et al. Growth failure in Niemann-Pick disease type B. 2015. ↩︎
McGovern MM, et al. Survival outcomes in Niemann-Pick disease type A. 2017. ↩︎
Mitchell WA, et al. Neuropathology of Niemann-Pick disease type A. 1997. ↩︎
Lofaso F, et al. Neuronal loss in NPD-A. 1985. ↩︎
Thomas GH, et al. Sphingomyelin accumulation in NPD. 1982. ↩︎
Crocker AC. The foam cell in Niemann-Pick disease. 1961. ↩︎
Rodriguez-Lafrasse C, et al. Early neurodegeneration in NPD-A. 1990. ↩︎
Thurberg BL, et al. Acid sphingomyelinase deficiency. 2015. ↩︎
Cassiman D, et al. Non-neuronopathic Niemann-Pick disease type B. 2016. ↩︎
Guillemot N, et al. Pulmonary disease in Niemann-Pick type B. 2017. ↩︎
McGovern MM, et al. Growth and development in Niemann-Pick disease type B. 2016. ↩︎
Geberhiwot T, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. 2018. ↩︎
Simonaro CM, et al. Pathology of NPD-B. 2002. ↩︎
Zhang H, et al. Pulmonary involvement in NPD-B. 2001. ↩︎
McGovern MM, et al. Bone disease in NPD-B. 2006. ↩︎
Biver A, et al. Cardiovascular risk in NPD-B. 2019. ↩︎
Sevin M, et al. Niemann-Pick disease type C: heterogeneous phenotypic presentation. 2007. ↩︎
Canbay A, et al. Neonatal liver failure in NPC. 2019. ↩︎
Solomon D, et al. Vertical supranuclear gaze palsy in NPC. 2019. ↩︎
Sedel F, et al. Neurological manifestations in Niemann-Pick disease type C. 2008. ↩︎
Kandt RS, et al. Cataplexy in Niemann-Pick disease type C. 2019. ↩︎
Fink JK, et al. Dementia in Niemann-Pick disease type C. 2019. ↩︎
Walkley SU, et al. Pathogenesis of NPC. 2020. ↩︎
Vance JE, et al. Cholesterol trafficking in NPC. 2006. ↩︎
Maxfield FR, et al. Lipid trafficking in NPC. 2001. ↩︎
Schulze H, et al. Autophagy in NPC. 2019. ↩︎
Yu D, et al. Mitochondrial dysfunction in NPC. 2019. ↩︎
Incerti G, et al. Epidemiology of NPD. 2020. ↩︎
Meikle PJ, et al. Prevalence of lysosomal storage disorders. 1999. ↩︎
Schuchman EH, et al. SMPD1 mutation database. 2009. ↩︎
Pavlu-Pereira H, et al. NPC1 mutation spectrum. 2005. ↩︎
Runz H, et al. NPC1 mutations in German patients. 2002. ↩︎
Schuchman EH. Acid sphingomyelinase and cell function. 2010. ↩︎
Ginzburg L, et al. ASM function in cellular signaling. 2004. ↩︎
Kolesnick RN, et al. Ceramide in apoptosis and disease. 2000. ↩︎
Payne AS, et al. ASM and apoptosis in NPD. 2002. ↩︎
Scott C, et al. NPC1 structure and function. 2008. ↩︎
Infante RE, et al. NPC2 structure and cholesterol binding. 2008. ↩︎
Vanier MT, et al. Endosomal/lysosomal storage disorders. 2013. ↩︎
Sleight BJ, et al. Lysosomal cholesterol trafficking. 2007. ↩︎
Patterson MC, et al. NPC disease mechanisms. 2013. ↩︎
Wasserstein MP, et al. [Olipudase alfa for treatment of Niemann-Pick disease type B](https://doi.org/10.1016/S0140-6736(22). 2022. ↩︎
Sanofi. Xenpozyme (olipudase alfa) prescribing information. 2022. 2022. ↩︎
Thurberg BL, et al. Efficacy of olipudase alfa in NPD-B. 2021. ↩︎
Kim S, et al. Pulmonary outcomes in olipudase alfa trial. 2022. ↩︎
Patterson MC, et al. Lipid profile changes with olipudase alfa. 2022. ↩︎
Jones SA, et al. Growth effects of olipudase alfa. 2022. ↩︎
Platt FM, et al. Blood-brain barrier in enzyme therapy. 2021. ↩︎
Thurberg BL, et al. Clinical trial results of olipudase alfa. 2022. ↩︎
European Medicines Agency. Miglustat (Zavesca). Product information. 2021. 2021. ↩︎
Platt FM, et al. Miglustat: mechanism of action. 2019. ↩︎
Lachmann RH. Miglustat: clinical practice guidelines. 2019. ↩︎
Patterson MC, et al. Miglustat for Niemann-Pick disease type C. 2020. ↩︎
Cole JA, et al. Miglustat and eye movements in NPC. 2021. ↩︎
Jiang X, et al. Biomarker response to miglustat in NPC. 2020. ↩︎
Evans WR, et al. Early miglustat treatment in NPC. 2021. ↩︎
Lachmann RH, et al. Miglustat side effects. 2014. ↩︎
Héron B, et al. Management of neurological symptoms in NPC. 2013. ↩︎
Wraith JE, et al. Supportive care in Niemann-Pick disease. 2010. ↩︎
Patterson MC, et al. Recommendations for monitoring NPC patients. 2019. ↩︎
Chandler RJ, et al. Gene therapy for Niemann-Pick disease. 2021. ↩︎
Dvorak-Ewell M, et al. Emerging therapies for NPD. 2022. ↩︎
McGovern MM, et al. Pulmonary management in NPD. 2019. ↩︎
Mengel E, et al. Respiratory disease in NPD. 2017. ↩︎
Héron B, et al. Infections in NPD. 2018. ↩︎
McGovern MM, et al. Portal hypertension in NPD. 2006. ↩︎
Wasserstein MP, et al. Nutritional issues in NPD. 2019. ↩︎
Héron B, et al. Antiepileptic therapy in NPC. 2019. ↩︎
Wraith JE, et al. Physical therapy in lysosomal storage disorders. 2018. ↩︎
Gieselmann V, et al. Speech therapy in NPD. 2020. ↩︎
Jones SA, et al. Biochemical diagnosis of NPD. 2015. ↩︎
Wraith JE, et al. ASM activity assay. 2010. ↩︎
Porter FD, et al. Plasma oxysterols as biomarkers. 2013. ↩︎
Wijburg FA, et al. Chitotriosidase in NPC. 2012. ↩︎
Patterson MC, et al. Genetic testing for NPD. 2011. ↩︎
Schuchman EH, et al. SMPD1 sequencing. 2009. ↩︎
NPC1 Consortium. NPC1 sequencing. Hum Mutat. 2006;27(10):1061-1062. 2006. ↩︎
Runz H, et al. NPC2 sequencing. 2008. ↩︎
Saito Y, et al. Brain MRI findings in NPC. 2011. ↩︎
Hori H, et al. Abdominal ultrasound in NPD. 2000. ↩︎
Guillemot N, et al. Chest CT in NPD-B. 2014. ↩︎
Runz H, et al. Natural history of NPD-A. 2008. ↩︎
McGovern MM, et al. Disease-modifying therapy in NPD. 2020. ↩︎
Vite CH, et al. AAV gene therapy for NPD. 2018. ↩︎
Hughes MP, et al. CRISPR approaches to NPC. 2019. ↩︎
Liu MM, et al. Novel SRIs for NPC. 2022. ↩︎
Dodge JC, et al. BBB-crossing ASM. 2021. ↩︎
Wasserstein MP, et al. Genotype-phenotype in NPD. 2018. ↩︎
Patterson MC, et al. Early intervention in NPC. 2020. ↩︎
Héron B, et al. Biomarkers for NPD treatment response. 2021. ↩︎